FDA Grants De Novo Classification Request to Market the World’s First Antibacterial Peptide-Based Wound Dressing

In granting the De Novo Classification Request, FDA allows Swedish medtech firm Amferia to market the first-ever wound care product featuring antibacterial peptides as the mechanism for fighting infection. The decision creates a new regulatory category for wound dressings in the U.S.

GOTHENBURG, SWEDEN—Amferia today announced that its antibacterial wound dressing has been granted approval by the U.S. Food and Drug Administration (FDA) through the De Novo Classification Request track, allowing Amferia to enter the U.S. market with a unique Class 2 medical device antibacterial dressing for advanced wound care.
 

Amferia’s patented technology is a hydrogel permanently bonded with peptides, which kill pathogenic bacteria by drawing them close and physically puncturing their cell membranes. Even antibiotic-resistant bacteria cannot effectively resist this interaction.

To confirm the dressing’s efficacy and safety for FDA regulators, Amferia was obliged to demonstrate that their novel mode of action kills 99.99% of bacteria exposed to it—an FDA threshold—without releasing active substances into the wound or the body.
 

The FDA’s approval of Amferia’s innovation establishes a new regulatory category for antimicrobial wound dressings and enables a unique and powerful tool in the worldwide battle against wound infection.  

Photo of Amferia Wound Dressing with permanently bound antibacterial peptides

“This approval validates years of scientific and regulatory work,” said Anand Rajasekharan, Amferia CEO & Co-Founder. “More importantly, it opens the door to safer, more sustainable ways to fight infection—at a time when the need for new antimicrobial strategies has never been greater.

“Bacterial infections are likely to surpass cancer and heart disease as a number one cause of human deaths in the future, and this is largely due to resistance to commonly used antibiotics. Our hydrogel technology enables the safe and stable use of antibacterial peptides, allowing them to effectively target bacteria without harming surrounding tissue.”

Studies on animal patients demonstrate that, in addition to effectively killing a broad spectrum of bacteria including antibiotic-resistant bacteria, Amferia dressings help support moist wound healing.

The FDA’s decision positions Amferia as a strategic partner for established wound care companies seeking next-generation antimicrobial solutions that align with evolving regulatory and safety expectations. With FDA approval secured, Amferia expects heightened interest from industry partners and plans to expand the application of its peptide-based technology beyond wound care over time.
 

A Deliberate, Data-Driven Path to Approval

Early engagement with the FDA made clear that Amferia’s wound dressing was too novel to be reviewed through the traditional 510(k) pathway, which compares new treatments to existing products and determines if they are substantially equivalent. Since no anti-bacterial peptide products currently exist on the U.S. market, the FDA pointed Amferia toward the De Novo classification pathway—designed for low-to-moderate risk devices that are new to the market but can be demonstrated safe and effective through clinical test results.

Amferia worked closely with FDA reviewers to generate an extensive body of evidence addressing questions of safety, effectiveness, and risk mitigation. Laboratory tests proved that Amferia’s wound dressings meet the FDA’s stringent requirement that wound dressings calling themselves anti-bacterial kill at least 99.99% of bacteria they are exposed to. Advanced chemical analyses proved that the peptides remain permanently bound to the hydrogel and do not leach into surrounding wound or tissue.

At several points, FDA feedback resulted in additional testing requests, including expanded bacterial strain panels and further in-vivo safety studies. Amferia responded point-by-point, generating new data and refining its submission. Throughout the process, the FDA did not challenge the underlying science of the technology, focusing instead on ensuring that the novel mechanism could be clearly understood, reproducibly tested, and safely regulated.
 

The Race to Solve Global Antimicrobial Resistance

Antimicrobial resistance (AMR) is accelerating at a pace that threatens to become one of the leading causes of human mortality worldwide in coming decades. At least five million people are currently affected by infections caused by antibiotic resistance. In countries with a high incidence of resistant bacteria, a small wound can cause life-threatening infection that can’t be treated with traditional antibiotics.

Antimicrobial peptides are known for their ability to kill bacteria due to their positive electrostatic charge, which attracts the negatively charged infectious bacteria. This allows peptides to puncture bacterial membranes and destroy the cells. However, their fragility in biological environments has been a major challenge to developing peptides as a viable treatment—naturally occurring enzymes in the body can destroy them within seconds. The Amferia hydrogel technology solves that problem.

Amferia’s breakthrough is the development of a hydrogel platform, encasing the peptides in a solid protective gel. This design shields the vulnerable facets of peptides while allowing their bacteria-killing structures to remain exposed—and lethal to even antibiotic-resistant bacteria. Amferia's antibacterial hydrogel kills bacteria without harming surrounding body tissue.

Amferia’s Founders: (From left) – Anand Rajasekharan (CEO), Saba Atefyekta (Sales & Marketing Director) and Martin Andersson (Scientific Advisor)

“The hydrogel technology we’ve developed enables the safe and stable use of antimicrobial peptides—one of nature’s most powerful defenses—while preventing the enzyme degradation that has historically limited their use,” Rajasekharan said.

Research shows that combining Amferia’s peptide hydrogel platfrom with antibiotics can dramatically amplify their bactericidal effect—up to 64 times stronger—demonstrating its potential to reshape infection management.

At scale, the Amferia approach has the potential to reduce infection rates, lower healthcare costs, and provide new options for treating wounds where conventional antimicrobials are becoming less effective.

Amferia has already entered the animal health segment and signed commercial agreements with leading animal health companies in Europe such as Orkla Wound Care, Magnum Veterinariaa, Grovet BV and Biokema SA, to introduce a wound dressing that also kills resistant bacteria and is now expanding into new markets with further partnerships in the pipeline.

In December, 2025, Amferia announced the successful closure of a 3.5-million-euro investment round. The round was over-prescribed and spearheaded by existing owners and new investors, among whom are leading voices in wound care.

Looking Ahead

Amferia continues to expand its product pipeline, invest in research, and collaborate with global partners to redefine how infections are prevented and managed. By stabilizing one of nature’s most effective bacterial defenses, the company offers a transformative platform with the potential to strengthen antibiotic treatments and improve outcomes across healthcare.

Learn more about Amferia

https://www.amferia.com/

https://news.cision.com/amferia-ab/r/new-study-finds-innovative-peptide-hydrogel-restores-the-effectiveness-of-antibiotics-against-drug-r,c4067581

https://news.cision.com/amferia-ab/r/first-product-utilizing-amferia-antimicrobial-technology-launched-in-europe-for-animal-wound-care,c4058570

https://news.cision.com/amferia-ab/r/amferia-wins-red-dot-award-for-innovative-design-addressing-bacterial-infections-and-antibiotic-resi,c4063979

Media Contact

Anand Rajasekharan
CEO & Co-Founder, Amferia
+46 76 298 12 38
anandk@amferia.com